Table 8.
Characteristics of community living male adults enrolled in the FROST study.
| Characteristics | Nr of Patients |
|---|---|
| Men (n,%) | 797 (45.2) |
| Age (years, mean ± SD) | 55.75 ± 15.5 |
| Age classes (n,%) | |
| ≤50 | 337 (42.2) |
| 51–70 | 299 (37.5) |
| 71–90 | 153 (19.1) |
| ≥91 | 8 (1.0) |
| BMI (Kg/m2, mean ± SD) | 26.25 ± 3.47 |
| Parental osteoporosis and/or fractures (n,%) | 49 (6.1) |
| Sedentary lifestyle (n,%) | 347 (43.5) |
| Smoking habit (n,%) | |
| Current smokers | 178 (22.3) |
| Former smokers | 194 (24.3) |
| Alcohol intake (n,%) | |
| >4 unit/day | 40 (5.0) |
| Dizziness (n,%) | 38 (4.7) |
| Falls in the previous year (n,%) | 17 (2.1) |
| At least one disease affecting bone metabolism (n,%) * | 148 (18.5) |
| At least one drug affecting bone metabolism (n,%) # | 191 (23.9) |
| At least one fragility fracture (n, %) | 27 (3.3) |
| Diagnosis of osteoporosis (n,%) | 9 (1.1) |
| At least one antifracture treatment (n,%) | 13 (1.6) |
* The list of diseases affecting bone metabolism includes: diabetes, cancer, COPD, chronic kidney disease (KDIGO stage IV-V), inflammatory bowel diseases, gastrectomy, small bowel resections, malabsorption syndrome, rheumatoid arthritis or major rheumatic diseases, hyperthyroidism, multiple myeloma, celiac disease, primary hyperparathyroidism, hypogonadism. # The list of drugs affecting bone metabolism includes: steroids, aromatase inhibitors or androgen deprivation therapy, antiretroviral therapy, antiepilepctics, warfarin, PPI, thyroid hormones, loop diuretics, heparin, methotrexate, flutaininde, neuroleptics), hypogonadism, malabsorption syndrome.